The Patent Finder
US

Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy

US 10,139,399 In force
OverviewFamilyAssignmentsSources & methods

Also listed on Horizon Pharma Rheumatology LLC, an earlier holder on the record. The recorded assignments below show how it moved.

Term ends Jun 25, 2030 · High confidence

Filed Feb 27, 2018 as application 15/906,839 · Granted Nov 27, 2018
Base term, 20 years from filing
Today
20 years from filing
2010 2030
Clock starts
Jun 25, 2010
Term ends
Jun 25, 2030
Granted
Nov 27, 2018
base term fee events Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 9,377,454, to Jun 25, 2030. The term already ends on or before that date, so the cap shortened nothing.
2 of 2
Maintenance fees paid
Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.
13
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 2 of 2 maintenance fees are paid so far. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Jun 25, 2010, when application PCT/US2010/040082, the earliest non-provisional in its chain, was filed (this one was filed Feb 27, 2018)Jun 25, 2030High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capDisclaimer resolved from the filed document (refs US 9,377,454)resolves to Jun 25, 2030, no earlier than this term, so no changeHigh confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events2 of 2 maintenance fees paidIn forceHigh confidence
Computed term endThe steps above, in orderJun 25, 2030High confidence

Partial family

Application PCT/US2010/004008PCT application
no patent term
no patent term
Application PCT/US2010/040082PCT application
no patent term
no patent term
US 9,377,454In force
Jun 2030
Jun 2030
Application 15/165,318Abandoned
not computed
not computed
US 10,139,399this patent
Jun 2030
Jun 2030
US 10,823,727In force
Jun 2030
Jun 2030
US 11,639,927In force
Jun 2030
Jun 2030
US 11,598,767In force
Jun 2030
Jun 2030
8 of 13 applications in this family shown, earliest filings first. Partial: 1 of the 13 has no file history here, so its row comes from the patent's own record or names the application alone. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Jun 21, 2018
Reel 46171, frame 242
Rosario-jansen, Theresa; Wright, David ErickSavient Pharmaceuticals, Inc.Assignment of Assignor's Interest
Jun 21, 2018
Reel 46407, frame 373
Horizon Pharma USA Rheumatology LLCHorizon Pharma Rheumatology LLCChange of Name
Jun 21, 2018
Reel 46407, frame 630
Savient Pharmaceuticals, Inc.; Savient Pharma Holdings, LLCCrealta Pharmaceuticals LLCAssignment of Assignor's Interest
Jun 21, 2018
Reel 46408, frame 896
Crealta Pharmaceuticals LLCHorizon Pharma USA Rheumatology LLCChange of Name
Oct 24, 2018
Reel 47720, frame 68
Horizon Pharma Rheumatology LLC; HZNP Limited; Horizon Therapeutics, LLCCitibank, N.a.Security Agreement
Sep 7, 2022
Reel 61389, frame 507
Horizon Pharma Rheumatology LLCHorizon Therapeutics USA, Inc.Assignment of Assignor's Interest
Oct 31, 2022
Reel 61805, frame 76
Horizon Pharma Rheumatology LLCHorizon Therapeutics USA, Inc.Assignment of Assignor's Interest
Dec 1, 2022
Reel 62073, frame 930
Horizon Pharma Rheumatology LLCHorizon Therapeutics USA, Inc.Corrective Assignment to Correct the Name of the Assignee Previously Recorded on Reel 061805 Frame 0076. Assignor(S) Hereby Confirms the Assignment.
Oct 6, 2023
Reel 65154, frame 75
Citibank, N.a.Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.); HZNP Limited; Horizon Therapeutics U.S. Holding LLC (Successor in Interest to Horizon Therapeutics, LLC)Release of Security Interest
Oct 6, 2023
reel/frame not recorded
Citibank, N.a.Horizon Therapeutics USA, Inc. (FKA Horizon Pharma USA, Inc.)Release of Security Interest
Oct 6, 2023
reel/frame not recorded
Citibank, N.a.HZNP LimitedRelease of Security Interest
Oct 6, 2023
reel/frame not recorded
Citibank, N.a.Horizon Therapeutics U.S. Holding LLC (Successor in Interest to Horizon Therapeutics, LLC)Release of Security Interest
Nov 6, 2026
Reel 76662, frame 840
Horizon Therapeutics USA, Inc.Horizon Therapeutics Ireland DacAssignment of Assignor's Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited